Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

First‐Line Nivolumab In Stage IV Or Recurrent Non–Small‐Cell Lung Cancer

D. Carbone, M. Reck, L. Paz-Ares, Benjamin Creelan, Leora Horn, M. Steins, E. Felip, M. Van den Heuvel, T. Ciuleanu, F. Badin, N. Ready, J. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, J. Wrangle, D. Rodríguez-Abreu, H. Borghaei, G. Blumenschein, L. Villaruz, L. Havel, J. Krejčí, J. Jaime, Han Chang, W. J. Geese, P. Bhagavatheeswaran, A. Chen, M. Socinski
Published 2017 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Nivolumab has been associated with longer overall survival than docetaxel among patients with previously treated non–small‐cell lung cancer (NSCLC). In an open‐label phase 3 trial, we compared first‐line nivolumab with chemotherapy in patients with programmed death ligand 1 (PD‐L1)–positive NSCLC. METHODS We randomly assigned, in a 1:1 ratio, patients with untreated stage IV or recurrent NSCLC and a PD‐L1 tumor‐expression level of 1% or more to receive nivolumab (administered intravenously at a dose of 3 mg per kilogram of body weight once every 2 weeks) or platinum‐based chemotherapy (administered once every 3 weeks for up to six cycles). Patients receiving chemotherapy could cross over to receive nivolumab at the time of disease progression. The primary end point was progression‐free survival, as assessed by means of blinded independent central review, among patients with a PD‐L1 expression level of 5% or more. RESULTS Among the 423 patients with a PD‐L1 expression level of 5% or more, the median progression‐free survival was 4.2 months with nivolumab versus 5.9 months with chemotherapy (hazard ratio for disease progression or death, 1.15; 95% confidence interval [CI], 0.91 to 1.45; P=0.25), and the median overall survival was 14.4 months versus 13.2 months (hazard ratio for death, 1.02; 95% CI, 0.80 to 1.30). A total of 128 of 212 patients (60%) in the chemotherapy group received nivolumab as subsequent therapy. Treatment‐related adverse events of any grade occurred in 71% of the patients who received nivolumab and in 92% of those who received chemotherapy. Treatment‐related adverse events of grade 3 or 4 occurred in 18% of the patients who received nivolumab and in 51% of those who received chemotherapy. CONCLUSIONS Nivolumab was not associated with significantly longer progression‐free survival than chemotherapy among patients with previously untreated stage IV or recurrent NSCLC with a PD‐L1 expression level of 5% or more. Overall survival was similar between groups. Nivolumab had a favorable safety profile, as compared with chemotherapy, with no new or unexpected safety signals. (Funded by Bristol‐Myers Squibb and others; CheckMate 026 ClinicalTrials.gov number, NCT02041533.)
This paper references
Mutation burden, neoantigens, and response to T cell checkpoint blockade
M. Hellmann (2016)
10.1097/JTO.0000000000000366
PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer
R. Zinner (2015)
10.1056/NEJMOA1606774
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
M. Reck (2016)
Mutation burden , neo - antigens , and response to T cell checkpoint blockade
M Hellmann
10.1200/JCO.2014.32.15_SUPPL.8024
First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.
S. Gettinger (2014)
[New response evaluation criteria in solid tumours-revised RECIST guideline (version 1.1)].
H. Watanabe (2009)
Mutation burden, neoantigens, and response to T cell checkpoint blockade
M. Hellmann (2016)
10.1056/NEJMoa1504627
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
J. Brahmer (2015)
10.1016/J.YONC.2012.07.002
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
A. Tsao (2012)
10.1016/S1470-2045(15)70046-X
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
L. Paz-Ares (2015)
10.1200/JCO.2007.15.0375
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
G. Scagliotti (2008)
10.1016/J.JTHO.2016.11.343
OA20.01 Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
M. Kowanetz (2017)
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus peme - trexed in chemotherapy - naive patients with advanced - stage non - small - cell lung cancer
GV Scagliotti (2015)
10.1093/ANNONC/MDW383.15
Long-term outcomes with nivolumab (Nivo) vs docetaxel (Doc) in patients (Pts) with advanced (Adv) NSCLC: CheckMate 017 and CheckMate 057 2-y update
F. Barlési (2016)
10.1186/s12916-017-0819-3
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
J. Remon (2017)
10.1126/science.aaa1348
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
10.1016/S1470-2045(15)00021-2
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
N. Thatcher (2015)
10.1200/JCO.2017.74.6065
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
N. Hanna (2017)
10.1200/JCO.2015.62.1342
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
G. Masters (2015)
10.1200/JCO.2016.66.9929
Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
S. Gettinger (2016)
10.1016/S1556-0864(15)31609-9
Survival Differences by Sex for Patients with Advanced Non-small Cell Lung Cancer on Eastern Cooperative Oncology Group Trial 1594
H. Wakelee (2006)
10.1200/JCO.2012.47.9626
PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.
J. Patel (2013)
10.6004/JNCCN.2016.0031
NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016.
D. Ettinger (2016)
Tumor mutation burden ( TMB ) is associated with improved efficacy of atezolizu - mab in 1 L and 2 L + NSCLC patients
M Kowanetz
10.1056/NEJMoa1507643
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
H. Borghaei (2015)



This paper is referenced by
10.2185/JJRM.68.797
免疫関連有害事象のためニボルマブ休薬後,再投与にて重篤な有害事象の再発なく長期奏効を得たPD-L1陰性進行非小細胞肺癌の1例
T. Chiaki (2020)
10.5772/INTECHOPEN.77005
Immunotherapy in Advanced Lung Cancer Treatment
A. Grigorescu (2018)
10.1007/s00262-019-02446-1
Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer
Y. Ozaki (2019)
10.1021/acs.chemrev.8b00396
Metal Drugs and the Anticancer Immune Response.
B. Englinger (2019)
10.1016/S1877-1203(18)30002-8
Les essais cliniques princeps en immuno-oncologie dans les cancers broncho-pulmonaires
Maurice Pérol (2018)
10.1016/j.lungcan.2019.01.017
Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer.
S. Zhao (2019)
10.1007/978-3-319-95228-4_29
Predictive Biomarkers and Targeted Therapies in Immuno-oncology
H. Koeppen (2019)
10.21037/tlcr.2018.08.14
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.
M. Allgäuer (2018)
10.2217/FON-2019-0105
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
R. Woodford (2019)
10.1002/cam4.1387
The benefit and risk of nivolumab in non‐small‐cell lung cancer: a single‐arm meta‐analysis of noncomparative clinical studies and randomized controlled trials
Binghao Zhao (2018)
10.1016/j.jtho.2017.11.111
Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer.
M. Socinski (2018)
10.1042/BSR20192347
Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
J. Shao (2020)
10.7888/juoeh.40.173
Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC).
K. Yoneda (2018)
10.1007/s15004-019-6652-4
Pembrolizumab: bei höherer PD-L1-Expression hoch effektiv
A. Schalhorn (2019)
10.1001/jamanetworkopen.2018.0416
A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors
B. Gyawali (2018)
10.1002/cam4.1234
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab‐treated patients with advanced non–small cell lung cancer
T. Shiroyama (2018)
10.1007/s15004-018-6133-1
Technische Entwicklungen in der molekularen Gewebeanalytik
Roberto Pappesch (2018)
10.1093/annonc/mdy334
PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
J. Sabari (2018)
10.1158/1078-0432.CCR-18-2823
Predicting Treatment Response Based on RNA Expression in Large Datasets
A. Mansfield (2018)
10.1007/s00432-019-02889-0
Impact of EGFR mutation on the clinical efficacy of PD-1 inhibitors in patients with pulmonary adenocarcinoma
J. Cho (2019)
10.2147/CMAR.S167400
Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors
Y. Zhu (2018)
10.18632/oncotarget.22242
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
A. Botticelli (2017)
10.1158/1078-0432.CCR-16-3065
Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity
V. Anagnostou (2017)
10.1016/j.jtho.2019.06.020
Pathologic considerations and standardization in mesothelioma clinical trials.
M. Tsao (2019)
10.1080/2162402X.2020.1836766
Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers
Soleine Medjebar (2020)
10.1016/j.cllc.2020.02.016
Minimally Invasive Lobectomy for Residual Primary Tumors of Advanced Non-Small-Cell Lung Cancer After Treatment With Immune Checkpoint Inhibitors: Case Series and Clinical Considerations.
J. Baek (2020)
10.1016/j.thorsurg.2020.01.009
Principles of Immunotherapy in Non-Small Cell Lung Cancer.
Melinda L Hsu (2020)
10.1016/j.critrevonc.2020.102948
Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC).
Finn Mildner (2020)
10.21037/tlcr-20-192
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Jiaqi Liang (2020)
10.1080/1354750X.2020.1794042
Clinical and molecular characteristics associated with survival among cancer patients receiving first-line anti-PD-1/PD-L1-based therapies
Yaojie Zhou (2020)
10.1016/j.jfma.2019.08.023
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost.
C. Kuo (2019)
10.1158/0008-5472.CAN-19-0231
Circulating Tumor DNA Provides a Sneak Peek into Treatment Responses in Non-Small Cell Lung Cancer.
Tao Zou (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar